Development of a model to predict 5-year risk of severe hypoglycemia in patients with type 2 diabetes.

Pubmed ID: 30116541

Pubmed Central ID: PMC6091902

Journal: BMJ open diabetes research & care

Publication Date: Aug. 12, 2018

Affiliation: Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Saint Paul, Minnesota, USA.

Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6091902/pdf/bmjdrc-2018-000527.pdf?link_time=2024-04-26_07:08:56.647462

Grants: N01HC95184, Y01 HC009035, N01HC95181, N01HC95179, N01HC95182, N01HC95180, N01HC95178, N01HC95183

Authors: Seaquist ER, Schreiner PJ, Chow LS, Zmora R, Ma S

Cite As: Chow LS, Zmora R, Ma S, Seaquist ER, Schreiner PJ. Development of a model to predict 5-year risk of severe hypoglycemia in patients with type 2 diabetes. BMJ Open Diabetes Res Care 2018 Aug 12;6(1):e000527. doi: 10.1136/bmjdrc-2018-000527. eCollection 2018.

Studies:

Abstract

OBJECTIVE: We constructed a predictive model of long-term risk for severe hypoglycemia (SH: hypoglycemia requiring assistance) in patients with type 2 diabetes (T2DM). RESEARCH DESIGN AND METHODS: Data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study (original n=10 251, n=5135 used in the current analysis), a randomized, multicenter, double 2×2 factorial design study examining the effect of glycemic, blood pressure, and lipid control on cardiovascular outcomes in patients with diagnosed T2DM, were used. Over the follow-up (3.76±1.12 years), the ACCORD participants experienced 607 incident SH events. Cox regression was used to identify the SH risk prediction model. RESULTS: We identified 17 predictors-glycemic management, age, race, education, waist circumference, medications (insulin, antihypertensive, HMG-CoA reductase inhibitors, sulfonylurea, biguanide and meglitinide), years since diabetes diagnosis, history of hypoglycemia in the last week, systolic blood pressure, diastolic blood pressure, serum creatinine, and urinary albumin creatinine ratio-to construct a prediction model for SH (c-statistic=0.782). Using this information, we derived point scores to estimate the 5-year risk for SH in individual patients with T2DM. After adjusting for other variables in the model, the three strongest predictors for SH over 5 years were intensive glycemic management (HR=2.37, 95% CI 1.99 to 2.83), insulin use (HR=2.14, 95% CI 1.77 to 2.59), and antihypertensive medication use (HR=1.90, 95% CI 1.26 to 2.86). CONCLUSION: Using the ACCORD data, we identified attributes to predict 5-year risk of SH in patients with T2DM, which warrant evaluation in broader populations to determine applicability.